Nikolian Vahagn C, Georgoff Patrick E, Pai Manjunath P, Dennahy Isabel S, Chtraklin Kiril, Eidy Hassan, Ghandour Mohamed H, Han Yanyan, Srinivasan Ashok, Li Yongqing, Alam Hasan B
From the Department of Surgery (V.C.N., P.E.G., I.S.D., K.C., H.E., M.G., Y.L., H.B.A.), University of Michigan, Ann Arbor, Michigan; Department of Clinical Pharmacy (M.P.P.), College of Pharmacy, University of Michigan, Ann Arbor, Michigan; Department of Pharmaceutical Sciences (Y.H.), College of Pharmacy, University of Michigan, Ann Arbor, Michigan; and Department of Radiology, Section of Neuroradiology (A.S.), University of Michigan, Ann Arbor, Michigan.
J Trauma Acute Care Surg. 2017 Dec;83(6):1066-1073. doi: 10.1097/TA.0000000000001612.
We have previously shown that treatment with valproic acid (VPA) decreases brain lesion size in swine models of traumatic brain injury (TBI) and controlled hemorrhage. To translate this treatment into clinical practice, validation of drug efficacy and evaluation of pharmacologic properties in clinically realistic models of injury are necessary. In this study, we evaluate neurologic outcomes and perform pharmacokinetic analysis of a single dose of VPA in swine subjected to TBI, hemorrhagic shock, and visceral hemorrhage.
Yorkshire swine (n = 5/cohort) were subjected to TBI, hemorrhagic shock, and polytrauma (liver and spleen injury, rib fracture, and rectus abdominis crush). Animals remained in hypovolemic shock for 2 hours before resuscitation with isotonic sodium chloride solution (ISCS; volume = 3× hemorrhage) or ISCS + VPA (150 mg/kg). Neurologic severity scores were assessed daily for 30 days, and brain lesion size was measured via magnetic resonance imaging on postinjury days (PID) 3 and 10. Serum samples were collected for pharmacokinetic analysis.
Shock severity and response to resuscitation were similar in both groups. Valproic acid-treated animals demonstrated significantly less neurologic impairment between PID 1 to 5 and smaller brain lesions on PID 3 (mean lesion size ± SEM, mm: ISCS = 4,956 ± 1,511 versus ISCS + VPA = 828 ± 279; p = 0.047). No significant difference in lesion size was identified between groups at PID 10 and all animals recovered to baseline neurologic function during the 30-day observation period. Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03). The mean ± SD maximum VPA concentrations, area under the curve, and half-life were 145 ± 38.2 mg/L, 616 ± 150 hour·mg/L, and 1.70 ± 0.12 hours.
In swine subjected to TBI, hemorrhagic shock, and polytrauma, VPA treatment is safe, decreases brain lesion size, and reduces neurologic injury compared to resuscitation with ISCS alone. These benefits are achieved at clinically translatable serum concentrations of VPA.
Therapeutic (preclinical study).
我们之前已经表明,在创伤性脑损伤(TBI)和控制性出血的猪模型中,丙戊酸(VPA)治疗可减小脑损伤大小。为了将这种治疗方法应用于临床实践,有必要在临床实际的损伤模型中验证药物疗效并评估其药理学特性。在本研究中,我们评估了单剂量VPA对遭受TBI、失血性休克和内脏出血的猪的神经学结局,并进行了药代动力学分析。
约克夏猪(每组n = 5)遭受TBI、失血性休克和多发伤(肝脾损伤、肋骨骨折和腹直肌挤压伤)。动物在低血容量休克状态下维持2小时,然后用等渗氯化钠溶液(ISCS;体积 = 出血体积的3倍)或ISCS + VPA(150 mg/kg)进行复苏。连续30天每天评估神经严重程度评分,并在伤后第3天和第10天通过磁共振成像测量脑损伤大小。收集血清样本进行药代动力学分析。
两组的休克严重程度和对复苏的反应相似。丙戊酸治疗的动物在伤后第1至5天神经功能损害明显较轻,伤后第3天脑损伤较小(平均损伤大小±标准误,mm:ISCS组 = 4,956 ± 1,511,ISCS + VPA组 = 828 ± 279;p = 0.047)。在伤后第10天,两组之间的损伤大小无显著差异,并且在30天观察期内所有动物均恢复到基线神经功能。接受VPA治疗的动物神经认知恢复更快(开始测试的天数,平均值±标准差:ISCS组 = 6.2 ± 1.6,ISCS + VPA组 = 3.6 ± 1.5;p = 0.002;掌握任务的天数:ISCS组 = 7.0 ± 1.0,ISCS + VPA组 = 4.8 ± 0.5;p = 0.03)。VPA的平均±标准差最大浓度、曲线下面积和半衰期分别为145 ± 38.2 mg/L、616 ± 150小时·mg/L和1.70 ± 0.12小时。
在遭受TBI、失血性休克和多发伤的猪中,与单独使用ISCS复苏相比,VPA治疗是安全的,可减小脑损伤大小并减轻神经损伤。在临床可转化的VPA血清浓度下可实现这些益处。
治疗性(临床前研究)。